87 related articles for article (PubMed ID: 27742066)
1. The 21st century revolution in CLL: Why this matters to patients.
Koffman B; Schorr A
Best Pract Res Clin Haematol; 2016 Mar; 29(1):122-132. PubMed ID: 27742066
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017.
Jakšić B; Pejša V; Ostojić-Kolonić S; Kardum-Skelin I; Bašić-Kinda S; Coha B; Gverić-Krečak V; Vrhovac R; Jakšić O; Aurer I; Sinčić-Petričević J; Načinović-Duletić A; Nemet D
Acta Clin Croat; 2018 Mar; 57(1):190-215. PubMed ID: 30256032
[TBL] [Abstract][Full Text] [Related]
3. Supportive care in patients with acute leukaemia: historical perspectives.
Cannas G; Thomas X
Blood Transfus; 2015 Apr; 13(2):205-20. PubMed ID: 25369611
[No Abstract] [Full Text] [Related]
4. Adaptive Interventions to Promote Change in the 21st Century: The Responsive Feedback Approach.
Viswanath K; Agha S
Glob Health Sci Pract; 2023 Dec; 11(Suppl 2):. PubMed ID: 38110199
[TBL] [Abstract][Full Text] [Related]
5. B cell receptor inhibition as a target for CLL therapy.
Jeyakumar D; O'Brien S
Best Pract Res Clin Haematol; 2016 Mar; 29(1):2-14. PubMed ID: 27742069
[TBL] [Abstract][Full Text] [Related]
6. The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia.
Jeyakumar D; O'Brien S
Oncology (Williston Park); 2016 Nov; 30(11):1008-15. PubMed ID: 27854102
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapy of CLL.
Al-Sawaf O; Fischer K; Eichhorst B; Hallek M
Oncol Res Treat; 2016; 39(12):768-778. PubMed ID: 27889784
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers.
Amaya-Chanaga CI; Rassenti LZ
Best Pract Res Clin Haematol; 2016 Mar; 29(1):79-89. PubMed ID: 27742074
[TBL] [Abstract][Full Text] [Related]
9. Current state of hematopoietic cell transplantation in CLL as smart therapies emerge.
Kharfan-Dabaja MA; El-Asmar J; Awan FT; Hamadani M; Ayala E
Best Pract Res Clin Haematol; 2016 Mar; 29(1):54-66. PubMed ID: 27742072
[TBL] [Abstract][Full Text] [Related]
10. Targeting BTK through microRNA in chronic lymphocytic leukemia.
Bottoni A; Rizzotto L; Lai TH; Liu C; Smith LL; Mantel R; Reiff S; El-Gamal D; Larkin K; Johnson AJ; Lapalombella R; Lehman A; Plunkett W; Byrd JC; Blachly JS; Woyach JA; Sampath D
Blood; 2016 Dec; 128(26):3101-3112. PubMed ID: 27756747
[TBL] [Abstract][Full Text] [Related]
11. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
Seftel MD; Kuruvilla J; Kouroukis T; Banerji V; Fraser G; Crump M; Kumar R; Chalchal HI; Salim M; Laister RC; Crocker S; Gibson SB; Toguchi M; Lyons JF; Xu H; Powers J; Sederias J; Seymour L; Hay AE
Leuk Lymphoma; 2017 Jun; 58(6):1358-1365. PubMed ID: 27750483
[TBL] [Abstract][Full Text] [Related]
12. Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
Poole A; Girard N; Clayton F; Tantravahi SK
Leuk Lymphoma; 2017 May; 58(5):1258-1261. PubMed ID: 27750463
[No Abstract] [Full Text] [Related]
13. Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
Prica A; Baldassarre F; Hicks LK; Imrie K; Kouroukis T; Cheung M;
Clin Oncol (R Coll Radiol); 2017 Jan; 29(1):e13-e28. PubMed ID: 27746042
[TBL] [Abstract][Full Text] [Related]
14. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor.
Choi MY; Kashyap MK; Kumar D
Best Pract Res Clin Haematol; 2016 Mar; 29(1):40-53. PubMed ID: 27742071
[TBL] [Abstract][Full Text] [Related]
15. Sequencing of chronic lymphocytic leukemia therapies.
Barrientos JC
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):128-136. PubMed ID: 27913471
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
UK CLL Forum
Haematologica; 2016 Dec; 101(12):1563-1572. PubMed ID: 27756834
[TBL] [Abstract][Full Text] [Related]
17. Current Treatment of Chronic Lymphocytic Leukemia.
Jamroziak K; Puła B; Walewski J
Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
[TBL] [Abstract][Full Text] [Related]
18. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.
Stauder R; Eichhorst B; Hamaker ME; Kaplanov K; Morrison VA; Österborg A; Poddubnaya I; Woyach JA; Shanafelt T; Smolej L; Ysebaert L; Goede V
Ann Oncol; 2017 Feb; 28(2):218-227. PubMed ID: 27803007
[TBL] [Abstract][Full Text] [Related]
19. Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors.
Kubczak M; Szustka A; Błoński JZ; Gucký T; Misiewicz M; Krystof V; Robak P; Rogalińska M
Mol Med Rep; 2019 May; 19(5):3593-3603. PubMed ID: 30864706
[TBL] [Abstract][Full Text] [Related]
20. Measure for measure: minimal residual disease in CLL.
Little RF; McShane LM
Blood; 2016 Dec; 128(24):2747-2748. PubMed ID: 27979863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
